The drug ABREVA contains one active pharmaceutical ingredient (API):
The exact mechanism of the antiviral activity of docosanol is unknown. In vitro studies indicate that docosanol affects the fusion between the virus and the plasma membrane, which inhibits intracellular uptake and replication of virus. Docosanol has no effect against non-enveloped viruses.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This brand name is authorized in the following countries: Canada
This drug has been assigned below unique identifiers within the countries it is being marketed: